Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 6/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571755 | 0.99 | KDM4E (0.66) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL572541 | 0.89 | KDM4E (0.67) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL30402766 | 0.89 | KDM4E (0.67) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL954152 | 0.88 | KDM4E (0.70) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL1284211 | 0.82 | LTA4H (0.56) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL1964818 | 0.82 | KDM4E (0.66) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL6201365 | 0.82 | KDM4E (0.63) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL22348748 | 0.82 | LTA4H (0.62) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL6200538 | 0.81 | KDM4E (0.64) | KDM4EMEN1KMT2AHTTLTA4H | |
| SCHEMBL1962920 | 0.81 | KDM4E (0.67) | KDM4EMEN1KMT2AHTTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | KDM4E 1551/4885MEN1 4074/4885KMT2A 2815/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | KDM4E 736/4885MEN1 3739/4885KMT2A 1381/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | KDM4E 736/4885MEN1 3739/4885KMT2A 1381/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | KDM4E 1551/4885MEN1 4074/4885KMT2A 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.